---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000069"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-07-14T23:59:59+00:00"
generated_at: "2026-05-18T06:39:51.670796+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Salarius gets additional Nasdaq extension to late July 2025 for equity standard compliance

## Summary
- Nasdaq Hearings Panel extended deadline to regain Equity Standard compliance to late July 2025.
- Minimum Bid Price Requirement must be met by early August 2025.
- On Jan 13, 2025, Salarius announced a merger agreement with Decoy Therapeutics; combined company to be named Decoy Therapeutics.
- Failure to meet milestones could trigger delisting; previous deadline for equity standard was early July 2025.
- Merger closing conditions remain; Decoy's CEO Rick Pierce will lead combined company.

## SEC filing metadata
- accession: 0001615219-25-000069
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-07-14T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000069/0001615219-25-000069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000069/flks-20250710.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000069
- JSON: https://secwatch.observer/filing/0001615219-25-000069.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.